Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from insulin glargine 100 U/ml to insulin glargine 300 U/ml in type 2 diabetes with renal impairment
2024-518403-22-00Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Primary endpoint: Change from baseline to Month 5 in the percentage of Time in Range (TIR). Started Jan 2025; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-518403-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518403-22-00.